Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights.

Buchanan AL, Hudgens MG, Cole SR, Mollan KR, Sax PE, Daar ES, Adimora AA, Eron JJ, Mugavero MJ.

J R Stat Soc Ser A Stat Soc. 2018 Oct;181(4):1193-1209. doi: 10.1111/rssa.12357. Epub 2018 Feb 26.

PMID:
30555215
2.

Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis.

Lancaster KE, Hoffman IF, Hanscom B, Ha TV, Dumchev K, Susami H, Rose S, Go VF, Reifeis SA, Mollan KR, Hudgens MG, Piwowar-Manning EM, Richardson P, Dvoriak S, Djoerban Z, Kiriazova T, Zeziulin O, Djauzi S, Ahn CV, Latkin C, Metzger D, Burns DN, Sugarman J, Strathdee SA, Eshleman SH, Clarke W, Donnell D, Emel L, Sunner LE, McKinstry L, Sista N, Hamilton EL, Lucas JP, Duong BD, Van Vuong N, Sarasvita R, Miller WC; HPTN 074 Study Team.

J Int AIDS Soc. 2018 Oct;21(10):e25195. doi: 10.1002/jia2.25195.

3.

Ultra-long-acting removable drug delivery system for HIV treatment and prevention.

Kovarova M, Benhabbour SR, Massud I, Spagnuolo RA, Skinner B, Baker CE, Sykes C, Mollan KR, Kashuba ADM, García-Lerma JG, Mumper RJ, Garcia JV.

Nat Commun. 2018 Oct 8;9(1):4156. doi: 10.1038/s41467-018-06490-w.

4.

A crowdsourced intervention to promote hepatitis B and C testing among men who have sex with men in China: study protocol for a nationwide online randomized controlled trial.

Fitzpatrick T, Zhou K, Cheng Y, Chan PL, Cui F, Tang W, Mollan KR, Guo W, Tucker JD.

BMC Infect Dis. 2018 Sep 29;18(1):489. doi: 10.1186/s12879-018-3403-3.

5.

A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study.

Miller WC, Hoffman IF, Hanscom BS, Ha TV, Dumchev K, Djoerban Z, Rose SM, Latkin CA, Metzger DS, Lancaster KE, Go VF, Dvoriak S, Mollan KR, Reifeis SA, Piwowar-Manning EM, Richardson P, Hudgens MG, Hamilton EL, Sugarman J, Eshleman SH, Susami H, Chu VA, Djauzi S, Kiriazova T, Bui DD, Strathdee SA, Burns DN.

Lancet. 2018 Sep 1;392(10149):747-759. doi: 10.1016/S0140-6736(18)31487-9.

PMID:
30191830
6.

Crowdsourcing to expand HIV testing among men who have sex with men in China: A closed cohort stepped wedge cluster randomized controlled trial.

Tang W, Wei C, Cao B, Wu D, Li KT, Lu H, Ma W, Kang D, Li H, Liao M, Mollan KR, Hudgens MG, Liu C, Huang W, Liu A, Zhang Y, Smith MK, Mitchell KM, Ong JJ, Fu H, Vickerman P, Yang L, Wang C, Zheng H, Yang B, Tucker JD.

PLoS Med. 2018 Aug 28;15(8):e1002645. doi: 10.1371/journal.pmed.1002645. eCollection 2018 Aug.

7.

Involving both parents in HIV prevention during pregnancy and breastfeeding.

Chi BH, Rosenberg NE, Mweemba O, Powers KA, Zimba C, Maman S, Kasaro M, Mollan KR, Stringer JS, Mutale W.

Bull World Health Organ. 2018 Jan 1;96(1):69-71. doi: 10.2471/BLT.17.200139. Epub 2017 Nov 27. No abstract available. Erratum in: Bull World Health Organ. 2018 Mar 1;96(3):220.

8.

Generalisability of an online randomised controlled trial: an empirical analysis.

Wang C, Mollan KR, Hudgens MG, Tucker JD, Zheng H, Tang W, Ling L.

J Epidemiol Community Health. 2018 Feb;72(2):173-178. doi: 10.1136/jech-2017-209976. Epub 2017 Nov 28.

9.

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.

Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW; AIDS Clinical Trials Group.

J Infect Dis. 2017 Sep 1;216(5):554-564. doi: 10.1093/infdis/jix248.

10.

The Relationship Between Efavirenz as Initial Antiretroviral Therapy and Suicidal Thoughts Among HIV-Infected Adults in Routine Care.

Bengtson AM, Pence BW, Mollan KR, Edwards JK, Moore RD, OʼCleirigh C, Eaton EF, Eron JJ, Kitahata MM, Mathews WC, Crane H, Mugavero MJ.

J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):402-408. doi: 10.1097/QAI.0000000000001510.

11.

Vaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocol.

Price JT, Mollan KR, Fuseini NM, Freeman BL, Mulenga HB, Corbett AH, Vwalika B, Stringer JSA.

Pilot Feasibility Stud. 2017 Jul 18;4:21. doi: 10.1186/s40814-017-0170-7. eCollection 2018. Erratum in: Pilot Feasibility Stud. 2017 Oct 24;3:48.

12.

Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies.

Wohl DA, Allmon AG, Evon D, Hurt C, Reifeis SA, Thirumurthy H, Straub B, Edwards A, Mollan KR.

Open Forum Infect Dis. 2017 May 5;4(2):ofx095. doi: 10.1093/ofid/ofx095. eCollection 2017 Spring.

13.

Estimating HIV Medication Adherence and Persistence: Two Instruments for Clinical and Research Use.

Wohl DA, Panter AT, Kirby C, Magnus BE, Hudgens MG, Allmon AG, Mollan KR.

AIDS Behav. 2018 Mar;22(3):948-960. doi: 10.1007/s10461-017-1772-z.

PMID:
28447269
14.

Increasing JAK/STAT Signaling Function of Infant CD4+ T Cells during the First Year of Life.

Dela Peña-Ponce MG, Rodriguez-Nieves J, Bernhardt J, Tuck R, Choudhary N, Mengual M, Mollan KR, Hudgens MG, Peter-Wohl S, De Paris K.

Front Pediatr. 2017 Feb 21;5:15. doi: 10.3389/fped.2017.00015. eCollection 2017.

15.

Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection.

Maas BM, Francis O, Mollan KR, Lee C, Cottrell ML, Prince HM, Sykes C, Trezza C, Torrice C, White N, Malone S, Hudgens MG, Sharpless NE, Dumond JB.

PLoS One. 2016 Dec 30;11(12):e0168709. doi: 10.1371/journal.pone.0168709. eCollection 2016.

16.

Corrigendum: The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.

Clutton G, Xu Y, Baldoni PL, Mollan KR, Kirchherr J, Newhard W, Cox K, Kuruc JD, Kashuba A, Barnard R, Archin N, Gay CL, Hudgens MG, Margolis DM, Goonetilleke N.

Sci Rep. 2016 Oct 3;6:34430. doi: 10.1038/srep34430. No abstract available.

17.

Balancing Trained Immunity with Persistent Immune Activation and the Risk of Simian Immunodeficiency Virus Infection in Infant Macaques Vaccinated with Attenuated Mycobacterium tuberculosis or Mycobacterium bovis BCG Vaccine.

Jensen K, Dela Pena-Ponce MG, Piatak M Jr, Shoemaker R, Oswald K, Jacobs WR Jr, Fennelly G, Lucero C, Mollan KR, Hudgens MG, Amedee A, Kozlowski PA, Estes JD, Lifson JD, Van Rompay KK, Larsen M, De Paris K.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00360-16. doi: 10.1128/CVI.00360-16. Print 2017 Jan.

18.

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.

Clutton G, Xu Y, Baldoni PL, Mollan KR, Kirchherr J, Newhard W, Cox K, Kuruc JD, Kashuba A, Barnard R, Archin N, Gay CL, Hudgens MG, Margolis DM, Goonetilleke N.

Sci Rep. 2016 Aug 2;6:30749. doi: 10.1038/srep30749. Erratum in: Sci Rep. 2016 Oct 03;6:34430.

19.

Point-of-Care Virologic Testing to Improve Outcomes of HIV-Infected Children in Zambia: A Clinical Trial Protocol.

Chibwesha CJ, Ford CE, Mollan KR, Stringer JS.

J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2:S197-201. doi: 10.1097/QAI.0000000000001050.

20.

Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques.

Jensen K, Nabi R, Van Rompay KKA, Robichaux S, Lifson JD, Piatak M Jr, Jacobs WR Jr, Fennelly G, Canfield D, Mollan KR, Hudgens MG, Larsen MH, Amedee AM, Kozlowski PA, De Paris K.

J Virol. 2016 Jul 27;90(16):7285-7302. doi: 10.1128/JVI.00481-16. Print 2016 Aug 15.

21.

Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.

Cottrell ML, Prince HM, Allmon A, Mollan KR, Hudgens MG, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Patterson KB, Kashuba AD.

J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):498-506. doi: 10.1097/QAI.0000000000000996.

22.

Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.

Tashima KT, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, Andrade A, Johnson VA, Eron JJ, Smeaton L, Haubrich RH.

HIV Clin Trials. 2015 Aug;16(4):147-56. doi: 10.1179/1945577115Y.0000000001. Epub 2015 Jul 27.

23.

The interplay between immune maturation, age, chronic viral infection and environment.

Oxford KL, Dela Pena-Ponce MGA, Jensen K, Eberhardt MK, Spinner A, Van Rompay KK, Rigdon J, Mollan KR, Krishnan VV, Hudgens MG, Barry PA, De Paris K.

Immun Ageing. 2015 May 9;12:3. doi: 10.1186/s12979-015-0030-3. eCollection 2015.

24.

Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.

Jabara CB, Hu F, Mollan KR, Williford SE, Menezes P, Yang Y, Eron JJ, Fried MW, Hudgens MG, Jones CD, Swanstrom R, Lemon SM.

Antimicrob Agents Chemother. 2014 Oct;58(10):6079-92. doi: 10.1128/AAC.03466-14. Epub 2014 Aug 4.

25.

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE, Gulick RM, Na L, O'Keefe L, Robertson KR, Tierney C.

Ann Intern Med. 2014 Jul 1;161(1):1-10. doi: 10.7326/M14-0293. Erratum in: Ann Intern Med. 2014 Aug 19;161(4):308.

Supplemental Content

Loading ...
Support Center